Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – Calidi Biotherapeutics Inc. (NYSE American: CLDI) to Present Breakthrough Virotherapy Platform at AACR 2025

Calidi Biotherapeutics (NYSE American: CLDI), a clinical-stage biotechnology company specializing in targeted antitumor virotherapies, announced its abstract, “Development of a Systemic Enveloped Virotherapy for Targeting All Metastatic Sites,” has been accepted for presentation at the American Association for Cancer Research (“AACR”) Annual Meeting, April 25-30, 2025, in Chicago. The presentation will highlight Calidi’s proprietary RTNova systemic platform, which leverages a novel vaccinia virus strain enveloped with a human cell membrane to overcome immune system elimination, enabling targeted delivery to multiple metastatic tumor sites. This innovative approach aims to address treatment challenges in advanced metastatic cancers, such as lung cancer, where intratumoral administration is impractical. CEO Allan Camaisa emphasized the platform’s potential to redefine metastatic cancer treatment by improving patient outcomes. In addition to the AACR presentation, Calidi plans to share further RTNova data at the ASCO Annual Meeting in June 2025, advancing its efforts to select a lead clinical candidate while progressing its localized virotherapies SNV (SuperNova) and NNV (NeuroNova).

To view the full press release, visit: https://ibn.fm/aSJJf

About Calidi Biotherapeutics

Calidi Biotherapeutics specializes in proprietary technology that empowers the immune system to combat cancer. The company’s novel stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in multiple oncology indications, including high-grade gliomas and solid tumors. Calidi’s clinical stage off-the-shelf, universal cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Calidi’s preclinical off-the-shelf enveloped virotherapies are designed to target disseminated solid tumors. This dual approach can potentially treat, or even prevent, metastatic disease. Calidi Biotherapeutics is headquartered in San Diego, California.

For more information, please visit www.calidibio.com

About MissionIR

MissionIR (“MIR”) is a specialized communications platform with a focus on assisting IR firms with syndicated content to enhance the visibility of private and public companies within the investment community. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, MIR is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, MIR brings its clients unparalleled recognition and brand awareness.

MIR is where breaking news, insightful content and actionable information converge.

For more information, please visit www.MissionIR.com

Please see full terms of use and disclaimers on the MissionIR website applicable to all content provided by MIR, wherever published or re-published: https://www.MissionIR.com/Disclaimer

MissionIR
Austin, Texas
www.MissionIR.com
512.354.7000 Office
[email protected]

MissionIR is powered by IBN

This entry was posted in NanoViricides Inc. NNVC. Bookmark the permalink.

Comments are closed.